Deletion of caspase-8 in mouse myeloid cells blocks microglia proinflammatory activation and confers protection in MPTP neurodegeneration model

Aging

Volumn 7, Issue 9, 2015, Pages 673-689

  Kavanagh, Edel ^a,b   Burguillos, Miguel Angel ^a   Carrillo Jimenez, Alejandro ^b   Oliva Martin, María José ^b   Santiago, Martiniano ^b   Rodhe, Johanna ^a   Joseph, Bertrand ^a   Venero, Jose Luis ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Instituto de Biomedicina de Sevilla   (Spain)

Author keywords

Caspace 8; Lipopolysaccharide; Microglia; MPTP; Parkinson's disease

Indexed keywords

ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; CASP8 PROTEIN, MOUSE; CASPASE 8; LIPOPOLYSACCHARIDE; LYSOZYME;

ANIMAL; BIOSYNTHESIS; BONE MARROW CELL; DOPAMINERGIC NERVE CELL; ENZYMOLOGY; GENETICS; GLIOSIS; INFLAMMATION; INTOXICATION; KNOCKOUT MOUSE; METABOLISM; MICROGLIA; MOUSE; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; CALCIUM-BINDING PROTEINS; CASPASE 8; DOPAMINERGIC NEURONS; GLIOSIS; INFLAMMATION; LIPOPOLYSACCHARIDES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MICROGLIA; MPTP POISONING; MURAMIDASE; MYELOID CELLS;

EID: 84943398594     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100805     Document Type: Article

References (55)

1. Hirsch EC and Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? The LancetNeurology. 2009; 8:382-397.
2. Tansey MG, McCoy MK and Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Experimental neurology. 2007; 208:1-25.
3. Hu X, Leak RK, Shi Y, Suenaga J, Gao Y, Zheng P and Chen J. Microglial and macrophage polarization-new prospects for brain repair. Nature reviews Neurology. 2015; 11:56-64.
4. Varnum MM and Ikezu T. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Archivum Immunologiae et Therapiae Experimentalis. 2012; 60:251-266.
5. Klegeris A, McGeer EG and McGeer PL. Therapeutic approaches to inflammation in neurodegenerative disease. Current Opinion in Neurology. 2007; 20:351-357.
6. McGeer PL, Itagaki S and McGeer EG. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathologica. 1988; 76:550-557.
7. McGeer PL and McGeer EG. Glial reactions in Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society. 2008; 23:474-483.
8. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE and Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Archives of Neurology. 2003; 60:1059-1064.
9. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G and Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Experimental Neurology. 2007; 205:295-312.
10. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A and Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Experimental Neurology. 1999; 156:50-61.
11. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM and Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nature Medicine. 1999; 5:1403-1409.
12. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R and Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. Journal of Neurochemistry. 2001; 76:1265-1274.
13. Holst O, Ulmer AJ, Brade H, Flad HD and Rietschel ET. Biochemistry and cell biology of bacterial endotoxins. FEMS Immunology and Medical Microbiology. 1996; 16:83-104.
14. Kielian TL and Blecha F. CD14 and other recognition molecules for lipopolysaccharide: a review. Immunopharmacology. 1995; 29:187-205.
15. Herrera AJ, Castano A, Venero JL, Cano J and Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiology of Disease. 2000; 7:429-447.
16. Castano A, Herrera AJ, Cano J and Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. Journal of Neurochemistry. 1998; 70:1584-1592.
17. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B and Hong JS. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. The Journal of neuroscience. 2000; 20:6309-6316.
18. Joseph B, Ekedahl J, Lewensohn R, Marchetti P, Formstecher P and Zhivotovsky B. Defective caspase-3 relocalization in nonsmall cell lung carcinoma. Oncogene. 2001; 20:2877-2888.
19. Venero JL, Burguillos MA and Joseph B. Caspases playing in the field of neuroinflammation: old and new players. Developmental Neuroscience. 2012; 35:88-101.
20. Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, Garcia-Quintanilla A, Cano J, Brundin P, Englund E, Venero JL and Joseph B. Caspase signalling controls microglia activation and neurotoxicity. Nature. 2011; 472:319-324.
21. Goldmann T, Wieghofer P, Muller PF, Wolf Y, Varol D, Yona S, Brendecke SM, Kierdorf K, Staszewski O, Datta M, Luedde T, Heikenwalder M, Jung S, et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nature Neuroscience. 2013; 16:1618-1626.
22. Ros-Bernal F, Hunot S, Herrero MT, Parnadeau S, Corvol JC, Lu L, Alvarez-Fischer D, Carrillo-de Sauvage MA, Saurini F, Coussieu C, Kinugawa K, Prigent A, Hoglinger G, et al. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:6632-6637.
23. Xing B, Bachstetter AD and Van Eldik LJ. Microglial p38alpha MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFalpha. Molecular Neurodegeneration. 2011; 6:84-1326-1326-1384.
24. Cho IH, Hong J, Suh EC, Kim JH, Lee H, Lee JE, Lee S, Kim CH, Kim DW, Jo EK, Lee KE, Karin M and Lee SJ. Role of microglial IKKbeta in kainic acid-induced hippocampal neuronal cell death. Brain. 2008; 131:3019-3033.
25. Tomas-Camardiel M, Rite I, Herrera AJ, de Pablos RM, Cano J, Machado A and Venero JL. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiology of Disease. 2004; 16:190-201.
26. Fricker M, Vilalta A, Tolkovsky AM and Brown GC. Caspase inhibitors protect neurons by enabling selective necroptosis of inflamed microglia. The Journal of Biological Chemistry. 2013; 288:9145-9152.
27. Kim SJ and Li J. Caspase blockade induces RIP3-mediated programmed necrosis in Toll-like receptor-activated microglia. Cell Death&Disease. 2013; 4:e716.
28. Kaczmarek A, Vandenabeele P and Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013; 38:209-223.
29. Kaiser WJ, Upton JW, Long AB, Livingston-RosanoffD, Daley-Bauer LP, Hakem R, Caspary T and Mocarski ES. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature. 2011; 471:368-372.
30. Hirai T, Uchida K, Nakajima H, Guerrero AR, Takeura N, Watanabe S, Sugita D, Yoshida A, Johnson WE and Baba H. The prevalence and phenotype of activated microglia/macrophages within the spinal cord of the hyperostotic mouse (twy/twy) changes in response to chronic progressive spinal cord compression: implications for human cervical compressive myelopathy. PloS one. 2013; 8:e64528.
31. Hu X, Li P, Guo Y, Wang H, Leak RK, Chen S, Gao Y and Chen J. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke. 2012; 43:3063-3070.
32. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ and Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. The Journal of Neuroscience. 2009; 29:13435-13444.
33. Villaran RF, Espinosa-Oliva AM, Sarmiento M, De Pablos RM, Arguelles S, Delgado-Cortes MJ, Sobrino V, Van Rooijen N, Venero JL, Herrera AJ, Cano J and Machado A. Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson's disease. Journal of Neurochemistry. 2010; 114:1687-1700.
34. Faucheux BA, Bonnet AM, Agid Y and Hirsch EC. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet. 1999; 353:981-982.
35. Issidorides MR. Neuronal vascular relationships in the zona compacta of normal and parkinsonian substantia nigra. Brain Research. 1971; 25:289-299.
36. Meredith GE and Rademacher DJ. MPTP mouse models of Parkinson's disease: an update. Journal of Parkinson's Disease. 2011; 1:19-33.
37. Yokoyama H, Kuroiwa H, Yano R and Araki T. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurological Sciences. 2008; 29:293-301.
38. Depboylu C, Stricker S, Ghobril JP, Oertel WH, Priller J and Hoglinger GU. Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Experimental Neurology. 2012; 238:183-191.
39. Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL, Rebrikov D, Brodianski VM, Kemper OC, Kollet O, Lapidot T, Soffer D, Sobe T, et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity. 1998; 9:267-276.
40. Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, Hakem R, Salvesen GS and Green DR. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature. 2011; 471:363-367.
41. Maelfait J and Beyaert R. Non-apoptotic functions of caspase-8. Biochemical Pharmacology. 2008; 76:1365-1373.
42. Oberst A and Green DR. It cuts both ways: reconciling the dual roles of caspase 8 in cell death and survival. Nature Reviews Molecular Cell Biology. 2011; 12:757-763.
43. Zhou W and Yuan J. Necroptosis in health and diseases. Seminars in Cell&Developmental Biology. 2014; 35C:14-23.
44. Lawson LJ, Perry VH, Dri P and Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience. 1990; 39:151-170.
45. Cuda CM, Misharin AV, Gierut AK, Saber R, Haines GK, 3rd, Hutcheson J, Hedrick SM, Mohan C, Budinger GS, Stehlik C and Perlman H. Caspase-8 acts as a molecular rheostat to limit RIPK1-and MyD88-mediated dendritic cell activation. Journal of immunology (Baltimore, Md: 1950). 2014; 192:5548-5560.
46. Gurung P, Anand PK, Malireddi RK, Vande Walle L, Van Opdenbosch N, Dillon CP, Weinlich R, Green DR, LamkanfiM and Kanneganti TD. FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes. Journal of Immunology (Baltimore, Md: 1950). 2014; 192:1835-1846.
47. Kang TB, Yang SH, Toth B, Kovalenko A and Wallach D. Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome. Immunity. 2013; 38:27-40.
48. Maelfait J, Vercammen E, Janssens S, Schotte P, Haegman M, Magez S and Beyaert R. Stimulation of Toll-like receptor 3 and 4 induces interleukin-1beta maturation by caspase-8. The Journal of Experimental Medicine. 2008; 205:1967-1973.
49. Arimoto T and Bing G. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiology of Disease. 2003; 12:35-45.
50. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y and Hirsch EC. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience. 1996; 72:355-363.
51. Le W, Rowe D, Xie W, Ortiz I, He Y and Appel SH. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2001; 21:8447-8455.
52. Hald A and Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Experimental Neurology. 2005; 193:279-290.
53. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. The Journal of Neuroscience 2002; 22:1763-1771.
54. Ch'en IL, Tsau JS, Molkentin JD, Komatsu M and Hedrick SM. Mechanisms of necroptosis in T cells. The Journal of Experimental Medicine. 2011; 208:633-641.
55. Gundersen HJ, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR and Pakkenberg B. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 1988; 96:857-881.